With over 450 deals announced, 2013 was a big year for mergers and acquisitions in the life sciences.
• Over 450 M&A deals announced during 2013, down from 500+ in 2012.
• The top 100 deals alone had a combined value of $150 billion.
• The leading M&A deal of the year was the acquisition of Life Technologies by Thermo Fisher in a deal valued at $13.6 billion.
• Twenty-six deals had value of or exceeding $1 billion.
• Most 2013 M&A deals involved big biotech and big pharma companies snapping up smaller companies in order to bolster pipeline and capabilities.
• An increasing number of deals are now incorporating contingent payments based on the future success of acquired company assets in achieving market launch and commercial success.
Derived from Current Agreements, the following is a summary of the key M&A deals trends of 2013 including most active acquirers, industry and therapy focus of acquired companies. There’s also full details of the top 50 life science M&A deals by deal value including acquired company, acquirer, headline value and other financials, industry sector and therapy area focus of the acquired company, plus link to full deal record supplied by our proprietary deals and alliances database.
The remaining part of this article is Premium content – see below for access options.
Purchase this article
$35.00 BUY NOW
For $35.00, purchase this 8,882-word article and receive immediate online access.
100% Satisfaction Guarantee.
Report: Merger and Acquisition Deals and Alliances of 2013
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity